Skip to content

Celsion details positive trial of ovarian cancer med

June 5, 2017

Shares of Celsion Corp. CLSN, +57.14% surged 14% in premarket trade Monday, after the cancer drug developer said an early-stage trial of a treatment of ovarian cancer showed promising findings. The phase 1b clinical trial evaluated Gen-1, the company’s DNA-based immunotherapy, with the standard care for patients with advanced ovarian cancer who will undergo chemotherapy followed by surgery. Of the 14 patients treated in the study, two demonstrated a complete response, ten a partial response, and two remained stable. “This translates to a 100% disease control rate (“DCR”) and an 86% objective response rate (“ORR”),” said the company. Celsion shares were down 40% in 2017 through Friday, while the S&P 500SPX, -0.08% has gained 9%.

http://on.mktw.net/2rKD7WO

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: